Papers from every journal, all in one place。 创建自定义信息流。
Perioperative dapagliflozin reduces postoperative AKI; extends SGLT2i use to cardiac surgery prevention.

nephrologist, Baylor College of Medicine
Hereon, investigators should aim to better understand the mechanism(s) by which SGLT2 inhibitors reduce the risk of AKI among patients undergoing elective cardiac surgery as well as those with type 2 diabetes, heart failure, and chronic kidney disease treated with SGLT2 inhibitors longer-term. Moreover, they should briskly and rigorously conduct randomized, placebo-controlled clinical trials of SGLT2 inhibitors in established AKI, aiming to arrest or attenuate its evolution and/or hasten its recovery.
First RCT of anti-inflammatory therapy in post-COVID cardiac involvement; leaves open whether losartan plus prednisolone improves symptoms or imaging.

Peer Reviewer, Springer Nature
The manuscript is well written, the introduction and aim are easy to follow, and the results are somewhat easy to follow. Notwithstanding, this reviewer is somewhat uneasy about the presentation of the changes in anatomical and functional measurements.
Cautions against over-relying on overlapping low-confidence meta-analyses; leaves open need for independent high-quality trials on GLP-1 RAs and AF.

Clinical Pharmacy, PlexusDx
Semaglutide is not absolutely contraindicated in atrial fibrillation, but individual cardiac history, current medications, and AFib severity must guide the decision. Recent data shows GLP-1 receptor agonists may offer cardiovascular benefits in certain patient populations, yet AFib presents unique arrhythmia-specific considerations that require personalized evaluation.
Prospective registry reports outcomes of bifurcation coronary interventions, indicating clinical pathways for optimal care.

Observational study reveals poor outcomes in medically managed non-ST elevation myocardial infarction patients, indicating the need for improved strategies.

Retrospective review assesses thrombolysis outcomes in patients with ST-elevation myocardial infarction, indicating clinical implications.

Home-based CR may expand access without loss of benefit; extends RCT evidence to Iranian settings.

Atenolol may reduce POAF after cardiac surgery; extends limited prior RCT data on this specific beta-blocker.

May support interpretable ECG analysis for PVC localization; leaves open prospective validation before clinical use.

LS7 improvements may lower recurrent CHD risk; extends secondary prevention evidence but leaves causality open without RCTs.
